Corbus to Present CRB-913 Study Data at Obesity Week 2026
Corbus Pharmaceuticals said late-breaking data from its CRB-913 Canyon-1 Phase 1B study will be presented as a poster at Obesity Week 2026.
Corbus Pharmaceuticals said late-breaking data from its CRB-913 Canyon-1 Phase 1B study will be presented as a poster at Obesity Week 2026.